In a 57‑kg adult (BMI ≈ 20 kg/m²) with hemoglobin A1c ≈ 10% who is on insulin glargine (Lantus) 10 U daily and now receiving an intravenous regular insulin infusion at 0.5 U per hour for an acute illness, what should the insulin glargine dose be?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Insulin Glargine Dose Adjustment During Acute Illness

For this 57‑kg patient (BMI ≈ 20 kg/m²) with A1c ≈ 10% on Lantus 10 U daily who now requires an additional 0.5 U/hour IV insulin infusion (12 U/day) during acute illness, increase the Lantus dose to approximately 16–18 units once daily when transitioning off the IV infusion.

Calculating the New Basal Insulin Requirement

  • The patient's total 24‑hour insulin requirement during acute illness is approximately 22 units (10 U baseline Lantus + 12 U from IV infusion at 0.5 U/hour × 24 hours) 1.

  • When transitioning from IV to subcutaneous insulin, give 50% of the total 24‑hour IV insulin dose as basal insulin, which equals approximately 6 units from the IV component 1.

  • Add this to the baseline Lantus requirement: 10 U (baseline) + 6 U (from IV) = 16 units as the new Lantus dose 1.

  • For a 57‑kg patient, this represents approximately 0.28 units/kg/day, which remains well below the 0.5 units/kg/day threshold where prandial insulin becomes necessary 2.

Critical Timing Considerations

  • Administer the new Lantus dose 2–4 hours before discontinuing the IV insulin infusion to prevent rebound hyperglycemia 1.

  • The IV infusion must overlap with subcutaneous insulin administration to maintain glycemic control during the transition 1.

Adjusting for Acute Illness Context

  • Insulin requirements increase during acute illness due to counter‑regulatory hormones and stress 2.

  • The A1c of 10% indicates chronic inadequate basal insulin coverage even before the acute illness, suggesting the baseline 10 units was already insufficient 2.

  • For this patient's weight (57 kg), a reasonable starting basal dose would typically be 0.1–0.2 units/kg/day (5.7–11.4 units), so the current 10 units was at the upper end of the initial dosing range 2.

Post‑Transition Titration Protocol

  • Once the acute illness resolves and the patient is stable, titrate the Lantus dose by 2–4 units every 3 days based on fasting glucose patterns 2.

  • Increase by 4 units every 3 days if fasting glucose ≥180 mg/dL, or by 2 units if fasting glucose is 140–179 mg/dL 2.

  • Target fasting glucose of 80–130 mg/dL 2.

  • If hypoglycemia occurs, reduce the dose by 10–20% immediately 2.

Monitoring Requirements During Transition

  • Check capillary blood glucose every 2–4 hours initially during and immediately after the transition from IV to subcutaneous insulin 1.

  • Monitor for signs of rebound hyperglycemia, which indicates inadequate basal coverage 1.

  • Monitor serum potassium closely as insulin drives potassium intracellularly, particularly important during acute illness 1.

Special Considerations for This Patient

  • The low BMI (≈ 20 kg/m²) suggests lower insulin resistance, meaning this patient may be more insulin‑sensitive than typical type 2 diabetes patients 2.

  • The A1c of 10% with only 10 units of Lantus indicates either poor adherence, inadequate dosing, or significant postprandial hyperglycemia requiring prandial insulin 2.

  • Once acute illness resolves, consider adding prandial insulin if the A1c remains >7% after 3–6 months of optimized basal insulin, starting with 4 units before the largest meal 2.

Common Pitfalls to Avoid

  • Do not simply continue the baseline 10 units when transitioning off IV insulin, as this will result in immediate rebound hyperglycemia 1.

  • Do not give the full 22 units as basal insulin, as approximately 50% should be allocated to prandial/correctional needs once eating resumes 1.

  • Do not delay the first subcutaneous dose until after stopping the IV infusion, as this creates a dangerous gap in insulin coverage 1.

  • Do not assume the increased requirement during acute illness will persist after recovery; plan to reassess and potentially reduce the dose once the acute illness resolves 2.

References

Guideline

Transitioning from IV to Subcutaneous Insulin in HHS

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How is the upward adjustment of insulin glargine (long-acting insulin) made in a patient with decompensated type 1 diabetes mellitus (DM1)?
What long-acting insulin (e.g. glargine) should be added to a patient's current regimen of 70/30 (Novolin 70/30, NPH/Regular insulin) 30 units twice daily, with an Hemoglobin A1c (HbA1c) level of severe hyperglycemia and no insurance coverage?
What discharge plan, including insulin regimen, diet, exercise, and adjunct therapies, should be recommended for a 53‑year‑old male with type 2 diabetes, hemoglobin A1c 12 %, BMI 40 (≈140 kg), currently on basal insulin glargine (Lantus) 50 U daily with a carbohydrate‑to‑insulin ratio of 1 U per 8 g carbohydrate and an insulin‑sensitivity factor of 25 mg/dL per unit, and bedside glucose readings of 200–300 mg/dL?
What adjustments should be made to the treatment plan for a patient with an A1C of 6.3% who is taking Lantus (insulin glargine) 13 units?
What would be a suggested Lantus (insulin glargine) sliding scale insulin for a sedentary diabetic male with an A1C of 8.5, and frequent postprandial blood glucose of 180 to 250 mg/dL?
In an adult with hypertension, ischemic heart disease or heart failure who is on a short‑acting β‑blocker that fails to control symptoms with once‑daily dosing, is twice‑daily dosing beneficial?
What is the diagnosis and recommended home treatment for a walk‑induced friction blister on the foot?
Can cilnidipine cause peripheral edema in an adult patient being treated for hypertension?
What is the most appropriate immediate management for a child who fell from a tree and now has head swelling, vomiting, and progressive drowsiness?
In a patient with an acute aortic dissection affecting both the ascending (type A) and descending (type B) aorta, what is the recommended immediate management, including surgical repair of the type A segment and medical therapy for the type B segment?
What antibiotic should be used to treat a confirmed Corynebacterium amycolatum infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.